Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study
Bogdan-Petru Tichil, Anamaria Besleaga, Ioana Gheorghiu, Alin-Dan Chiorean, Mihaela Laura Vica Matei, Adrian Florea · 2026
Read Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study by Bogdan-Petru Tichil, Anamaria Besleaga, Ioana Gheorghiu, Alin-Dan Chiorean, Mihaela Laura Vica Matei, Adrian Florea (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607581.txt.
Introduction
Bogdan-Petru Tichil and co-authors pilot a urine test pairing for bladder cancer in a 2026 study. Standard urine cytology catches high-grade tumors well but misses many low-grade ones. A gene called FGFR3 is often switched on in early, non-invasive bladder tumors, and two of its hot-spot mutations can be sought in urine DNA. The team ran both tests on paired urine samples from adults with confirmed bladder tumors at one center.
Samples were taken before any scope or instrument work, between early 2022 and late 2023. Cytology followed the standard Paris reporting system, and DNA tests used targeted assays for the two mutations. The pilot weighs whether the gene test catches cases that cytology leaves behind, which could sharpen non-invasive checks.
Catalog record
| CREATOR | Bogdan-Petru Tichil, Anamaria Besleaga, Ioana Gheorghiu, Alin-Dan Chiorean, Mihaela Laura Vica Matei, Adrian Florea |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study Authors: Bogdan-Petru Tichil, Anamaria Besleaga, Ioana Gheorghiu, Alin-Dan Chiorean, Mihaela Laura Vica Matei, Adrian Florea Published: 2026 ABSTRACT Background: Urinary cytology is routinely used as an adjunct to cystoscopy in the diagnosis and surveillance of urothelial carcinoma. Although it has high specificity for high-grade tumors, its sensitivity for low-grade papillary lesions is limited. Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are frequently encountered in non-muscle-invasive bladder cancer and may provide a complementary molecular method for detecting tumors that are not identified by conventional cytology. Objective: To compare conventional urinary cytology with urinary detection of the FGFR3 hotspot mutations S249C and R248C in patients undergoing evaluation for urothelial carcinoma. Materials and Methods: This single-center prospective pilot study included adult patients with clinically and radiologically confirmed bladder tumors evaluated between February 2022 and December 2023. Voided urine specimens were collected before cystoscopy or urinary tract instrumentation. Urine cytology was performed after centrifugation, conventional smear preparation, alcohol fixation, and Papanicolaou staining, with interpretation according to The Paris System for Reporting Urinary Cytology. DNA extracted from paired urine specimens was analyzed for the FGFR3 S249C and R248C hotspot mutations using TaqMan mutation-detection assays and real-time polymerase chain reaction. Histopathological examination of transurethral resection, bladder biopsy, or radical surgical specimens served as the reference standard. Results: Twenty-six patients were included, with a mean age of 69.2 ± 11.5 years; 24 patients (92.3%) were male. At least one FGFR3 mutation was detected in 17 patients (65.4%), whereas nine patients (34.6%) had no detectable mutation. The S249C mutation was identified in three patients, while the R248C mutation was detected in nine patients, 5 patients were positive for both mutations. 1. Introduction Bladder cancer (BC) is among the ten most frequently diagnosed malignancies worldwide and remains a major cause of morbidity, mortality, and healthcare expenditure. More than 600,000 new cases and 220,000 deaths occur annually, with increasing incidence because of population aging and continued exposure to carcinogens such as tobacco smoke and occupational aromatic amines [1]. More than 90% of bladder tumors are urothelial carcinomas; approximately 70–75% present as non-muscle-invasive bladder cancer (NMIBC), including Ta, T1, and carcinoma in situ (CIS), while the remainder are muscle-invasive at diagnosis [2,3,4]. Although NMIBC generally has favorable cancer-specific survival, 50–70% of patients experience recurrence and approximately 10–20% progress to muscle-invasive disease [5,6]. Repeated endoscopic procedures and prolonged surveillance consequently make bladder cancer one of the most expensive malignancies to manage per patient [7]. Guidelines from the European Association of Urology (EAU), American Urological Association/Society of Urologic Oncology (AUA/SUO), and National Comprehensive Cancer Network (NCCN) identify cystoscopy with histopathological confirmation following transurethral resection as the diagnostic standard [2,3,4]. Cystoscopy permits direct lesion visualization and tissue acquisition, while NMIBC surveillance remains based mainly on periodic cystoscopy because of the high recurrence risk [2,3]. Urinary biomarkers may provide complementary information in selected situations, but current molecular assays cannot replace cystoscopy across the full spectrum of urothelial carcinoma [2,3,4]. Urinary cytology has been used routinely for decades and remains recommended as an adjunct, particularly for suspected high-grade urothelial carcinoma, CIS, unexplained positive urinary findings despite negative cystoscopy, and surveillance of intermediate- or high-risk NMIBC [2,3,4]. Its principal value lies in detecting high-grade disease and providing cellular information that complements endoscopic findings [2,3,4]. Urine cytology is based on microscopic examination of exfoliated urothelial cells obtained from voided urine, bladder washings, or instrumented specimens. Malignant cells may show nuclear enlargement, hyperchromasia, coarse chromatin, irregular contours, increased nuclear-to-cytoplasmic ratio, and prominent nucleoli [8]. High-grade tumors generally exfoliate abundant atypical cells, whereas low-grade papillary tumors often retain near-normal architecture and release few abnormal cells; performance therefore depends on tumor biology, specimen quality, and cytopathological expertise [9,10]. Cytology has very high specificity, usually above 90% and often approaching 95–100% in experienced laboratories [11,12,13]. Overall sensitivity is lower, commonly 35–55%, and varies markedly by grade [11,14]. Sensitivity for high-grade carcinoma and CIS often reaches 70–90% or more [9,11,15], whereas low-grade tumors are frequently detected in fewer than 30% of cases because their cytological atypia is limited [11,14]. These limitations prompted the development of The Paris System for Reporting Urinary Cytology (TPS), which focuses primarily on identifying high-grade urothelial carcinoma rather than attempting reliable diagnosis of all urothelial neoplasms [16,17,18]. Its standardized categories—Negative for High-Grade Urothelial Carcinoma, Atypical Urothelial Cells, Suspicious for High-Grade Urothelial Carcinoma, and High-Grade Urothelial Carcinoma—improve communication and reduce interobserver variability [16,17,18,19]. Validation studies indicate that TPS enhances reproducibility without sacrificing specificity [17,18,19,20]. Nevertheless, cytological interpretation remains influenced by cellularity, fixation, preparation, and observer experience. Infection, instrumentation, intravesical Bacillus Calmette–Guérin therapy, urolithiasis, radiation, and inflammation may produce reactive atypia [8,16], while hypocellular specimens or poorly exfoliating tumors can cause false-negative results. Cytology therefore has strong positive predictive value but modest negative predictive value, especially for low-grade disease [11,12,13,14,15]. It is relatively inexpensive, generally costing US$30–100 per specimen [21,22], although repeated testing, confirmatory cystoscopy, and dependence on specialist interpretation limit its economic and diagnostic impact [17,18]. The poor sensitivity of cytology for low-grade tumors has encouraged the development of molecular urinary biomarkers that detect tumor-associated alterations independently of cell morphology. Among these, activating fibroblast growth factor receptor 3 (FGFR3) mutations are especially relevant because they arise early and are common in low-grade papillary NMIBC. FGFR3 encodes a transmembrane receptor tyrosine kinase involved in proliferation, differentiation, migration, apoptosis, and tissue homeostasis through pathways including RAS–MAPK, PI3K–AKT, PLCγ, and STAT [5,23,24]. Activating point mutations cause ligand-independent receptor dimerization and constitutive signaling, promoting urothelial tumorigenesis [24,25,26]. More than ten activating FGFR3 mutations have been described, but R248C, S249C, G372C, and Y375C account for most cases [24,27]. S249C is the most frequent mutation, followed by R248C, and together they represent more than half of FGFR3-mutated urothelial tumors [24]. Mutation frequencies may approach 70–80% in low-grade Ta NMIBC but are substantially lower in high-grade and muscle-invasive disease [23,25,28]. This distribution complements cytology: cytology performs best in high-grade tumors, whereas FGFR3 alterations predominate in low-grade lesions that often escape morphological detection. FGFR3-mutated low-grade tumors generally show lower proliferative and metastatic potential and a more indolent course than tumors driven by TP53 or RB1 alterations [29]. Although recurrence remains frequent, progression is comparatively uncommon, supporting FGFR3 activation as a distinct pathway of urothelial carcinogenesis and a potential surveillance marker [24,29]. Urinary FGFR3 assays detect tumor-derived DNA released into urine and may remain informative when intact atypical cells are scarce. Available platforms include allele-specific, real-time, and multiplex polymerase chain reaction, droplet digital polymerase chain reaction, and next-generation sequencing [30,31,32]. Modern assays can detect low mutant-allele fractions within abundant wild-type DNA [31]. Across studies, specificity has generally been high, although the performance of individual assays varies according to mutation prevalence, disease characteristics, specimen type, and analytical method [30,33]. Zuiverloon and colleagues demonstrated the feasibility of FGFR3 mutation analysis in voided urine during surveillance of patients with low-grade non-muscle-invasive bladder cancer [33], while other studies have similarly supported the potential role of urinary molecular testing in recurrence surveillance [34,35]. The present study therefore compared conventional urinary cytology with targeted urinary FGFR3 hotspot analysis for S249C and R248C in paired urine specimens from patients with histopathologically confirmed urothelial